Get the latest analysis on Heron Therapeutics (HRTX): current challenges, future outlook, and key growth factors. Click here ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that’s not necessarily what you pay.

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage.

President Trump announces a deal with Novo Nordisk and Eli Lilly to lower the cost of their blockbuster GLP-1 drugs, ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on.